|Dr. Denise Scots-Knight Ph.D.||Co-Founder, CEO & Exec. Director||1.2M||N/A||1959|
|Mr. Charles Sermon||Co-Founder, Gen. Counsel & Company Sec.||877.59k||N/A||1969|
|Dr. Alastair MacKinnon M.D., MBBS||Co-Founder and Chief of Portfolio & Pipeline Strategy||864.78k||N/A||1970|
|Dr. John P. Richard M.B.A., MBA||Co-Founder & Chief Bus. Officer||819.72k||N/A||1957|
|Dr. John A. Lewicki Ph.D.||Chief Scientific Officer||775.16k||N/A||1952|
|Ms. Alexandra Hughes-Wilson||Chief of Patient Access & Commercial Planning||496.63k||N/A||1971|
|Ms. Christine Fox CPA||Chief Financial Officer||N/A||N/A||1981|
|Dr. Fiona Bor||Head of Intellectual Property||N/A||N/A||N/A|
|Dr. Jackie Parkin||Therapy Area Head of Respiratory Endocrinology||N/A||N/A||N/A|
|Dr. Arun Mistry||Therapeutic Area Head of Setrusumab||N/A||N/A||N/A|
Mereo BioPharma Group plc, a biopharmaceutical company, acquires, develops, and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumor. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), a novel antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 antitrypsin deficiency. The company has a collaboration with The University of Texas MD Anderson Cancer Center to evaluate anti-TIGIT therapeutic antibody candidate, etigilimab. Mereo BioPharma Group plc was founded in 2015 and is based in London, the United Kingdom.
Mereo BioPharma Group plc’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.